NatMerkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S, Mekhoubad S, Ilic D, Charlton M, Saphier G, Handsaker RE, Genovese G, Bar S, Benvenisty N, McCarroll SA & Eggan K (2017)

Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature, 545: 229–233

Ref 28445466

Kastenhuber ER & Lowe SW (2017)

Putting p53 in Context. Cell, 170: 1062–1078

Ref 28886379

Joerger AC & Fersht AR (2016)

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem, 85: 375–404

Ref 27145840

 

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM (2015)

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature, 523: 352–356

Ref 26009011

Horii T, Yamamoto M, Morita S, Kimura M, Nagao Y, Hatada I (2015)

p53 Suppresses Tetraploid Development in Mice. Sci Rep 5: 8907.

Ref. 25752699

Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W (2015)

Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520: 57-62. 

Ref. 25799988 

 

Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R (2014)

p53Psi is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A 111: 3287-3296. 

Ref. 25074920

 

 

Bieging KT, Mello SS, Attardi LD (2014)

Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14: 359-370. 24739573

 Ref. 24739573

 

 

Go to top